Sirna, Alnylam, IDT, ABI, Ambion, CEA, New England Biolabs, Avecia, TriLink | GenomeWeb

Sirna Q4, 2005 Losses Fall on Lower Operating Costs

Sirna Therapeutics reported this week its financial results for the fourth-quarter and full-year 2005, posting a drop in losses amid lower operating costs.

For the fourth quarter, Sirna's net loss was $5.8 million, or $0.10 per share, versus a year-ago loss of $8.9 million, or $0.23 per share. For 2005, the company's net loss fell to $23.9 million, or $0.48 per share, from $28.9 million, or $0.81 per share.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.